

**Research Project: Assessment of Prescribing Pattern of Statins in Malaysian Type 2 Diabetic Patients Pre vs. Post Educational Intervention**

**Data Collection Form**

<b>Study Site:</b>	<b>Date:</b>	<b>Patient's ID:</b>
--------------------	--------------	----------------------

**A. Patient Characteristics:**

<b>Age:</b>	<b>Sex :</b>	<b>Race :</b>	<b>Weight &amp; height:</b>
<b>Tobacco use:</b>		<b>DM Onset:</b>	
<input type="radio"/> Smoker <input type="radio"/> Non-smoker <input type="radio"/> Ex-smoker		<input type="radio"/> 5 years and below <input type="radio"/> 5 to 10 years <input type="radio"/> More than 10 years	

**B. Indication For Treatment:**

Indication	
<input type="radio"/> Type 2 DM Only (1 <sup>st</sup> Prophylaxis)	<input type="radio"/> Type 2 DM & ASCVD (2 <sup>nd</sup> Prophylaxis)

**C. Laboratory Investigations**

Lab Investigations				
Type	Value		Reading	Date
LDL-C (mmol/L)	1 <sup>st</sup> Prophylaxis	2 <sup>nd</sup> Prophylaxis		
	<input type="radio"/> < / = 2.6 <input type="radio"/> > 2.6	<input type="radio"/> < / = 1.8 <input type="radio"/> > 1.8		
HDL-C (mmol/L)	Male	Female		
	<input type="radio"/> > 1 <input type="radio"/> < 1	<input type="radio"/> > 1.2 <input type="radio"/> < 1.2		
TG (mmol/L)	<input type="radio"/> < 1.7	<input type="radio"/> > 1.7		
Venous plasma glucose (mmol/L)	Fasting	Non-fasting		
	<input type="radio"/> 4.4–6.1 mmol/L <input type="radio"/> > 6.1 mmol/L	<input type="radio"/> 4.4–8.0 mmol/L <input type="radio"/> > 8.0 mmol/L		
A1c (%)	<input type="radio"/> < / = 6.5%	<input type="radio"/> > 6.5%		
Renal parameters	Creatinine value	Creatinine clearance		
	( 44-133 mmol/L)	<input type="radio"/> > 30 ml/min <input type="radio"/> < 30 ml/min		

Liver enzymes (U/L)	AST: (< 72 U/L)	ALT: (< 45 U/L)		
---------------------	-----------------	-----------------	--	--

**D. Drug Regimen: (statins/lipid lowering therapy)**

<b>Drug:</b>	<b>Dose:</b>	<b>Duration:</b>
	<input type="radio"/> 10 mg <input type="radio"/> 20 mg <input type="radio"/> 40 mg	<input type="radio"/> 1 – 2 months <input type="radio"/> 3 – 6 months <input type="radio"/> 1 year or above
<b>Treatment Modifications types</b>		
<input type="radio"/> Dose intensification	<input type="radio"/> Dose reduction	<input type="radio"/> Discontinuation
<input type="radio"/> Accretion	<input type="radio"/> Subtraction	<input type="radio"/> Switch from / to statin
<b>If any:</b>	<b>Date:</b>	

**E. Concomitant Diseases/ Medical History:**

Disease	Onset	Remarks
<b>ASCVD:</b> <input type="radio"/> CAD (coronary artery disease) <input type="radio"/> Stroke <input type="radio"/> PAD (peripheral artery disease)		
<b>Hypertension</b>		
<b>Muscle Disorders</b>		

**F. Concurrent Use Of Other Medications:**

Medications For Diabetes		Other Medications	
<u>Insulin</u>	Dose	Drug	Dose
<u>Oral Anti-diabetic agents</u>			